A study of Lanabecestat (LY3314814) in Early Alzheimer’s Disease Dementia
Study identifier:16557
ClinicalTrials.gov identifier:NCT02972658
EudraCT identifier:2016-003440-36
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Medical condition
Alzheimer's disease
Phase
Phase 3
Healthy volunteers
No
Study drug
Lanabecestat
Sex
All
Actual Enrollment
421
Study type
Interventional
Age
55 Years +
Date
Study Start Date: 15 Mar 2017
Primary Completion Date: 02 Oct 2018
Study Completion Date: 02 Oct 2018
Study design
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2019 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Eli Lilly and Company
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 |
| Experimental: AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 |
| Experimental: AZES Placebo/AZFD Lanabecestat 20 mg Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 |
| Experimental: AZES Placebo/AZFD Lanabecestat 50 mg Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 |
Contacts
Investigators
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
